205 related articles for article (PubMed ID: 27524889)
1. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.
Gelhorn HL; Bacci ED; Poon JL; Boye KS; Suzuki S; Babineaux SM
Patient Prefer Adherence; 2016; 10():1337-48. PubMed ID: 27524889
[TBL] [Abstract][Full Text] [Related]
2. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.
Gelhorn HL; Poon JL; Davies EW; Paczkowski R; Curtis SE; Boye KS
Patient Prefer Adherence; 2015; 9():1611-22. PubMed ID: 26635470
[TBL] [Abstract][Full Text] [Related]
3. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
[TBL] [Abstract][Full Text] [Related]
5. Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.
Brooks A; Langer J; Tervonen T; Hemmingsen MP; Eguchi K; Bacci ED
Diabetes Ther; 2019 Apr; 10(2):735-749. PubMed ID: 30847838
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
7. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.
Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G
Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406
[TBL] [Abstract][Full Text] [Related]
8. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
[TBL] [Abstract][Full Text] [Related]
10. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
[TBL] [Abstract][Full Text] [Related]
11. Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.
Rydén A; Chen S; Flood E; Romero B; Grandy S
Patient; 2017 Aug; 10(4):475-487. PubMed ID: 28315192
[TBL] [Abstract][Full Text] [Related]
12. A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.
Polster M; Zanutto E; McDonald S; Conner C; Hammer M
J Med Econ; 2010; 13(4):655-61. PubMed ID: 21034377
[TBL] [Abstract][Full Text] [Related]
13. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.
Gelhorn HL; Osumili B; Brown K; Ross MM; Schulz A; Fernandez G; Boye KS
Patient Prefer Adherence; 2023; 17():793-805. PubMed ID: 36987498
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
16. Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.
Thieu VT; Robinson S; Kennedy-Martin T; Boye KS; Garcia-Perez LE
Patient Prefer Adherence; 2019; 13():561-576. PubMed ID: 31114170
[TBL] [Abstract][Full Text] [Related]
17. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
[TBL] [Abstract][Full Text] [Related]
20. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS; Lebrec J; Dib A; Heitmann E; Federici MO; Yu M; Sapin H; Barrett A; Guerci B; Giorgino F; Füchtenbusch M; García-Pérez LE
Diabetes Obes Metab; 2023 Dec; 25(12):3453-3464. PubMed ID: 37712754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
